Recombinant Human nsIL12 Oncolytic Adenovirus (Beijing Haute Biotechnology)
重组人nsIL12溶瘤腺病毒（北京锤特生物科技）
Report date: 2026/03/31 20:00:21
Base Information
Drug NameRecombinant Human nsIL12 Oncolytic Adenovirus (Beijing Haute Biotechnology)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications +[7]
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing Bio-Targeting Therapeutics Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China
Develop Information
Active CompaniesHenan Provincial Cancer HospitalBeijing Bio-Targeting Therapeutics Technology Co LtdChina Medical University, China
Inactive CompaniesN/A
Active Indications +[5]
Inactive Indications
Other Information
ATC CodeN/A
Related LinksN/A